Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- Aricept to Receive 16.7-16.8% Reduction, Lyrica 25% in Re-Pricing Due to Market Expansion
March 6, 2012
- 702 Products Including DPP-4 Inhibitors to Be Eligible for New Drug Premium in April
March 5, 2012
- Private-Sector Members of Strategy Council Call for Early Establishment of Drug Discovery Support Organization
March 5, 2012
- Cancer Policy Promotion Council Submits New 5-Year Plan to Health Minister Komiyama
March 5, 2012
- 11 APIs/28 Products to Receive Premiums for New Pediatric, Orphan Indications
March 5, 2012
- Revised Ordinance Banning “Dispensing Point” Services Announced in Official Gazette
March 5, 2012
- PAFSC’s 2nd Committee on Drugs Recommends Approval for Pfizer Japan’s ALK Inhibitor Xalkori
March 1, 2012
- MHLW Study Group Approves Outline of “Post-5-Year Plan” for Promoting Clinical Trials
March 1, 2012
- PAFSC’s 2nd Committee on Drugs Recommends Orphan Drug Designation for 4 Products
February 29, 2012
- MHLW Conducts Hearing on Distribution Improvement with Drug Manufacturers
February 28, 2012
- Ikoma City Introduces Pharmacy Certification System to Promote Use of Generics
February 28, 2012
- Non-partisan Study Group Holds Hearings on Problem of Essential But Unprofitable Drugs
February 28, 2012
- Next 5-Year Strategy Calls for Boost to Japanese“Rising Sun”Seed Development
February 27, 2012
- PAFSC’s First Committee on Drugs Recommends Approval for Eli Lilly’s Once-Weekly GLP-1 Receptor Agonist
February 27, 2012
- National, Rosai Hospitals Hold 1st Meeting Aimed at Joint Purchasing in July
February 27, 2012
- Welfare Offices to Dispatch “Advisors” to Visit Welfare Recipients and Encourage Generic Drug Use
February 27, 2012
- Health Insurance Law Revision Study Group Formed, Calling for Legal Presence for Regulatory Guidance
February 24, 2012
- Measures to Eliminate Drug Lag “Fully Implemented”: GRU Report
February 24, 2012
- Novartis Pharma’s Pasireotide Designated as Orphan Drug for Cushing’s Disease
February 24, 2012
- PAFSC Committee on New Drugs Approves Orphan Drug Designation for 3 Products
February 24, 2012
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…